Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Regenerx
(OTCEM:RGRX)
Intraday
$0.0014
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$0.0014
0
[0.00%]
At close: Apr 17
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Regenerx Stock (OTC:RGRX)
Regenerx Stock (OTC: RGRX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, June 22, 2022
RegeneRx Licensee To Expand Phase 3 Clinical Trial Program With RGN-259
Benzinga Newsdesk
-
Jun 22, 2022, 8:34AM
Wednesday, May 31, 2017
REGEBXBIO Initiates Phase 1 Trial of RGX-314 Gene Therapy for Wet Age-Related Macular Degeneration
Benzinga
-
May 31, 2017, 7:10AM
Wednesday, April 06, 2016
RegeneRx To Receive EU Patent For Use Of Tβ4
Benzinga
-
Apr 6, 2016, 11:15AM
Monday, March 14, 2016
Benzinga's Top Initiations
Benzinga
-
Mar 14, 2016, 9:38AM
Rodman & Renshaw Initiates Coverage on Regenerx at Buy, Announces $2.00 PT
Benzinga
-
Mar 14, 2016, 7:02AM
Tuesday, June 02, 2015
Clinical Trial Shows Elevated Thymosin Beta 4 Plasma Levels are Associated with Improvement of Symptoms After Stem Cell Therapy in Patients with Ischemic Heart Failure
Benzinga
-
Jun 2, 2015, 8:31AM
Monday, October 20, 2014
RegeneRx Announces Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for Treatment of Neurotrophic Keratopathy
Benzinga
-
Oct 20, 2014, 10:14AM
Monday, April 21, 2014
RegeneRx Receives Notice of Allowance for Patent for Treatment of Stroke
Benzinga
-
Apr 21, 2014, 12:40PM
Friday, January 03, 2014
RegeneRx Announces Orphan Drug Designation for Tβ4 for Treatment of Neurotrophic Keratopathy
Benzinga
-
Jan 3, 2014, 8:25AM
Tuesday, November 29, 2011
RegeneRx Receives Notice of Allowance on U.S. Patent for Skin Protection and Repair
Benzinga
-
Nov 29, 2011, 8:31AM
Thursday, October 06, 2011
RegeneRx Receives Notice of Allowance for Key U.S. Heart Patent
Benzinga
-
Oct 6, 2011, 2:45PM
